chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Rash pruritic
Clinical narrative: Developed a very itchy rash on my back. It was about the size of my fist and lasted 3 days; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old male patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 10Apr2021 at 12:00 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, ragweed allergy (allergy to plants) and somewhat allergic to bee sting. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and hydrochlorothiazide (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021, the patient developed a very itchy rash on the back.  It was about the size of the patient's fist and lasted 3 days. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event itchy rash on the back was resolved 13Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Headache, Oropharyngeal pain, Pain, Pyrexia
Clinical narrative: pain all over the body; coughing; sore throat; fever; soreness on site; Headaches; This is a spontaneous report from a contactable healthcare professional, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 26Mar2021 at 16:30 (at the age of 62-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, arthritis and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did receive regular medicines within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 05:00, the patient experienced headaches, fever, pain all over the body, soreness on site, coughing and sore throat. The patient was in bed for four days. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events headaches, fever, pain all over the body, soreness on site, coughing and sore throat was resolved on an unknown date in 2021. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 16Apr2021 (at the age of 62-year-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: pain all over the body; coughing; sore throat; fever; soreness on site; Headaches; This is a spontaneous report from a contactable healthcare professional, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 26Mar2021 at 16:30 (at the age of 62-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, arthritis and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did receive regular medicines within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 05:00, the patient experienced headaches, fever, pain all over the body, soreness on site, coughing and sore throat. The patient was in bed for four days. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events headaches, fever, pain all over the body, soreness on site, coughing and sore throat was resolved on an unknown date in 2021. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 16Apr2021 (at the age of 62-year-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Heart rate, Heart rate increased
Clinical narrative: Muscle pain; Joint pain; Chills; Tiredness; Rapid pulse; Feeling unwell; Fever; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the right arm on 21Apr2021 at 13:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included prior stroke, complex post-traumatic stress disorder (PTSD) and degenerative disc disease. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient received other medications within two weeks of the COVID-19 vaccine, names were unspecified. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 31Mar2021 at 13:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient previously took azithromycin (MANUFACTURER UNKNOWN), amoxicillin; clavulanate potassium (AUGMENTIN), guaifenesin (MANUFACTURER UNKNOWN) all from an unknown date for an unspecified indication and experienced drug allergy. On 22Apr2021 at 01:00, the patient experienced muscle pain, joint pain, chills, tiredness, rapid pulse; Ave. 112 bpm, feeling unwell, fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. On 22Apr2021, the patient underwent heart rate and the result was 112 bpm. The clinical outcome of the events muscle pain, joint pain, chills, tiredness, rapid pulse; Ave. 112 bpm, feeling unwell, fever was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Myalgia, Pyrexia
Clinical narrative: Muscle pain; Joint pain; Chills; Tiredness; Rapid pulse; Feeling unwell; Fever; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the right arm on 21Apr2021 at 13:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included prior stroke, complex post-traumatic stress disorder (PTSD) and degenerative disc disease. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient received other medications within two weeks of the COVID-19 vaccine, names were unspecified. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 31Mar2021 at 13:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient previously took azithromycin (MANUFACTURER UNKNOWN), amoxicillin; clavulanate potassium (AUGMENTIN), guaifenesin (MANUFACTURER UNKNOWN) all from an unknown date for an unspecified indication and experienced drug allergy. On 22Apr2021 at 01:00, the patient experienced muscle pain, joint pain, chills, tiredness, rapid pulse; Ave. 112 bpm, feeling unwell, fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. On 22Apr2021, the patient underwent heart rate and the result was 112 bpm. The clinical outcome of the events muscle pain, joint pain, chills, tiredness, rapid pulse; Ave. 112 bpm, feeling unwell, fever was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Pruritus, Skin irritation
Clinical narrative: Itching sensation across body, no visible rash; Irritation on skin was present after physical scratching; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 01Apr2021 at 14:00 (at the age of 37 years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks prior to the COVID-19 vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 08:00, the patient had an itching sensation across the body with no visible rash but irritation on skin was present after physical scratching. The symptom emerged within 48 hours of vaccine and still persisted (at the time of reporting) but had become milder. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of adverse events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event itching sensation across the body with no visible rash, irritation on skin present after physical scratching was resolved with lasting effects on an unspecified date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Arthralgia, Pain in extremity, Sensitive skin
Clinical narrative: Joint aches; soreness in arm; stomach cramps; skin sensitivity; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 20Apr2021 at 12:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no allergies to food, medication or other products. Prior to the vaccination, the patient was not diagnosed with COVID. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication was not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP6955) via an unspecified route of administration in the right arm on 30Mar2021 at 12:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 14:30, the patient experienced joint aches, soreness in arm, stomach cramps and skin sensitivity. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event joint aches, soreness in arm, stomach cramps and skin sensitivity were recovered on an unknown date in Apr2021.   No follow-up attempts are needed; No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Fatigue, Feeling abnormal, Influenza like illness, Rhinorrhoea
Clinical narrative: Very sore bruised arm at the injection site; Slight cough; Sneezing; Runny nose; Feeling like a cold is coming; Weird feeling in head/ears; Tired; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the left arm on 21Apr2021 at 10:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included post-operative hypothyroidism, fibromyalgia, depression, anxiety and migraines. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the left arm on 31Mar2021 at 10:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patient previously took codeine (MANUFACTURER UNKNOWN) and sulfamethoxazole; trimethoprim (BACTRIM) and experienced drug allergy. On 22Apr2021 at 06:00, the patient experienced very sore bruised arm at the injection site, a slight cough, sneezing, runny nose, felt like a cold was coming (that weird feeling one gets in head/ears) and was a little extra tired but had no fever till the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events sore bruised arm at the injection site, slight cough, sneezing, runny nose, felt like a cold was coming (weird feeling in head/ears) and tired were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Sneezing, Vaccination site bruising
Clinical narrative: Very sore bruised arm at the injection site; Slight cough; Sneezing; Runny nose; Feeling like a cold is coming; Weird feeling in head/ears; Tired; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the left arm on 21Apr2021 at 10:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included post-operative hypothyroidism, fibromyalgia, depression, anxiety and migraines. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the left arm on 31Mar2021 at 10:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patient previously took codeine (MANUFACTURER UNKNOWN) and sulfamethoxazole; trimethoprim (BACTRIM) and experienced drug allergy. On 22Apr2021 at 06:00, the patient experienced very sore bruised arm at the injection site, a slight cough, sneezing, runny nose, felt like a cold was coming (that weird feeling one gets in head/ears) and was a little extra tired but had no fever till the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events sore bruised arm at the injection site, slight cough, sneezing, runny nose, felt like a cold was coming (weird feeling in head/ears) and tired were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Urticaria
Clinical narrative: Delayed rash (hives) stomach, legs, back of arms, back and buttocks; Delayed rash (hives) stomach, legs, back of arms, back and buttocks; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 11Apr2021 at 16:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included pcos (polycystic ovarian syndrome) and high blood pressure. The patient had known allergies to sulfa, tea tree oil and detergent. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Mar2021 at 16:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 14Apr2021 at 08:00, the patient experienced delayed rash (hives) on stomach, legs, back of arms, back and buttocks. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of reported event which included treatment with a round of prednisone (MANUFACTURER UNKNOWN) of 40mg. The clinical outcome of events delayed rash (hives) on stomach, legs, back of arms, back and buttocks was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Dizziness, Hypoaesthesia oral, Joint stiffness, Vertigo
Clinical narrative: I felt dizzy, the lights and furniture were swinging/spinning. I felt my brain physically rolled/moved inside my head.; I felt dizzy, the lights and furniture were swinging/spinning./ I felt my brain physically rolled/moved inside my head.; My mouth seemed num/tongue was not following his brain; My jaw was slow. Just not normal.; But the adverse effects on 04/21 night really worries me.; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 19Apr2021 at 11:15 (at the age of 57-year -old) as a single dose for COVID-19 immunisation. Medical history included colon (Unspecified disorder of intestine). The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 02:00, first time ever, at night in bed after midnight, when the patient moved the head felt dizzy, the lights and furniture were swinging/spinning. The patient felt that the brain physically rolled/moved inside the head. The patient woke his wife (multiple times) and his mouth seemed num. This occurred multiple times. The patient tried multiple times to see if it was his illusion (The patient really wished it was). The patient tested multiple times; it was really true (The patient was an engineer). In the early morning, when the patient made a phone call, he still felt that the tongue was not following his brain. The patient jaw was slow. Just not normal. The patient got the second shot on 19Apr2021, this side effect occurred at the night of 21Apr2021. The patient had relatively severe adverse effect on the first night 19Apr2021 after the second shot "(but it was fine I guess)", but the adverse effects on 21Apr2021 night really worries. The patient didn't have much feeling on the first shot though. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events head felt dizzy, the lights and furniture were swinging/spinning, brain physically rolled/moved inside the head, mouth seemed num, tongue was not following brain and jaw slow were unknown at the time of this report  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine, Neck pain
Clinical narrative: Migraine started about a minute after the shot; Immediate tension to neck; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Mar2021 at 14:15 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Medical history included chronic migraine. The patient had no known allergies to medications, food or other products. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any medications within two weeks of vaccination. On 23Mar2021 at 14:15, the patient had immediate tension to her neck and about a minute after the shot, the patient experienced migraine. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The patient did not receive any treatment for the reported events. The clinical outcome of the events immediate tension to neck and migraine was recovered on an unknown date in 2021. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 14:15 (at the age of 22-year-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Axillary pain, Disease recurrence, Joint swelling, Lymphadenopathy
Clinical narrative: This happened twice: 36 hours after the second vaccine and subsided after about 48 hours. It occurred again in April 14 and remains swollen and painful as of 4/22; Swelling in left arm pit lymph nodes; Pain and swelling in arm pit; Swelling in armpit, shoulder blade, and side; Pain and swelling in armpit, shoulder blade, and side; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8375) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included pneumonia in Jan2021. The patient did not have allergies to medications, food, or other products.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ENG62R) via an unspecified route of administration in the arm left on 01Mar2021 at 13:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 14Apr2021 at 20:00, the patient experienced swelling in left arm pit lymph nodes that caused pain and swelling in arm pit, shoulder blade, and side. This happened twice, 36 hours after the second vaccine and subsided after about 48 hours. It occurred again on 14Apr2021 and remained swollen as of 22Apr2021, the day of reporting. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with anti-inflammatory medications and hot compress. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling in left arm pit lymph nodes that caused pain and swelling in arm pit, shoulder blade, and side was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Dry throat, Headache, Nasal congestion, Oropharyngeal pain
Clinical narrative: Headache; Stuffy nose; Throat was sore and dry; Throat was sore and dry; Arm was sore; Ran a slight fever, just hitting 100 degrees; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 19Apr2021 at 10:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and allergy to nuts. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medication included fexofenadine hydrochloride (ALLEGRA) from an unknown date for an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021, day after vaccination, the patient's arm was sore and ran a slight fever, just hitting 100 degrees. The next day on 21Apr2021, the patient had a stuffy nose and throat was sore and dry. On 22Apr2021 (the day after 21Apr2021), the patient's nose was still stuffy, throat was still dry, and had a headache and slight fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events arm was sore, ran a slight fever, just hitting 100 degrees, stuffy nose, throat was sore and dry and headache was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: Headache; Stuffy nose; Throat was sore and dry; Throat was sore and dry; Arm was sore; Ran a slight fever, just hitting 100 degrees; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 19Apr2021 at 10:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and allergy to nuts. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medication included fexofenadine hydrochloride (ALLEGRA) from an unknown date for an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021, day after vaccination, the patient's arm was sore and ran a slight fever, just hitting 100 degrees. The next day on 21Apr2021, the patient had a stuffy nose and throat was sore and dry. On 22Apr2021 (the day after 21Apr2021), the patient's nose was still stuffy, throat was still dry, and had a headache and slight fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events arm was sore, ran a slight fever, just hitting 100 degrees, stuffy nose, throat was sore and dry and headache was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Livedo reticularis
Clinical narrative: Red skin; mottled skin on left (more) and right (less) shin; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 18Apr2021 at 11:45 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, obstructive sleep apnea and penicillin allergy. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and octinoxate, octocrilene (SOLARIS); all taken on an unknown date for unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 28Mar2021 at 12:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 09:00, the patient experienced red skin, mottled skin on left (more) and right (less) shin, not itchy. The patient did not receive any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event red skin, mottled skin on left (more) and right (less) shin was recovering at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Disorientation, Feeling abnormal, Headache
Clinical narrative: Disorientation; Body aches; Brain fog; Sweats; Joint pain (especially in knees and lower back); Mild headache; Nausea; Chills; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route on 21Apr2021 at 10:15 hours in the left arm (at an age of 19-year-old) as single dose for COVID-19 immunisation. Prior to vaccination, the patient was diagnosed with COVID-19. The medical history of the patient included dairy allergy. The patient received ethinylestradiol, norethisterone acetate (JUNEL FE 24) within 2 weeks of COVID-19 vaccine for birth control. The patient did not receive any other vaccination within 4 weeks of vaccination. Previously, the patient also received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route on 31Mar2021 at 10:15 hours in the left arm as single dose for COVID-19 immunisation. On 21Apr2021, 9 hours post vaccination, at 21:15 hours, the patient had chills, sweats, body aches and joint pain (especially in knees and lower back), brain fog or disorientation (possibly due to headache), mild headache and nausea and were still ongoing. It was 24 hours post second vaccination at the time of this report. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of chills, sweats, body aches and joint pain (especially in knees and lower back), brain fog or disorientation, mild headache and nausea were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperhidrosis, Nausea, Pain
Clinical narrative: Disorientation; Body aches; Brain fog; Sweats; Joint pain (especially in knees and lower back); Mild headache; Nausea; Chills; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route on 21Apr2021 at 10:15 hours in the left arm (at an age of 19-year-old) as single dose for COVID-19 immunisation. Prior to vaccination, the patient was diagnosed with COVID-19. The medical history of the patient included dairy allergy. The patient received ethinylestradiol, norethisterone acetate (JUNEL FE 24) within 2 weeks of COVID-19 vaccine for birth control. The patient did not receive any other vaccination within 4 weeks of vaccination. Previously, the patient also received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route on 31Mar2021 at 10:15 hours in the left arm as single dose for COVID-19 immunisation. On 21Apr2021, 9 hours post vaccination, at 21:15 hours, the patient had chills, sweats, body aches and joint pain (especially in knees and lower back), brain fog or disorientation (possibly due to headache), mild headache and nausea and were still ongoing. It was 24 hours post second vaccination at the time of this report. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of chills, sweats, body aches and joint pain (especially in knees and lower back), brain fog or disorientation, mild headache and nausea were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Anogenital warts
Clinical narrative: Anal wart outbreak after receiving 1st vaccine.; This is a spontaneous report from a contactable consumer. A male patient of 64-year-old age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was EN6202), first dose on right arm via an unspecified route of administration on 13-MAR-2021 10:15 at unknown DOSE 1, SINGLE for COVID-19 immunization. He received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was ER2613), on left arm via an unspecified route of administration on 03Apr2021, 10:15 for COVID-19 immunization. No medical history reported. Concomitant medication included Multivitamin Allegra (received within 2 weeks of vaccination). Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19. On 15Mar2021 patient experienced Anal wart outbreak after receiving 1st vaccine. The outcome of Event was not recovered.  No follow up attempts are possible. Information about lot/batch number cannot be requested. No further information is expected.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: 5 days following the 2nd shot I experienced a sudden outbreak of hives on my torso, armpits and groin. The hives settled but returned suddenly the following day, but less severe. A small outbreak occurred late in the 3rd day.; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 12Apr2021 at 17:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history. The patient had no known allergies to medications, food, or other products. The patient did not receive any concomitant medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6206) via an unspecified route of administration in the left arm on 17Mar2021 at 17:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021 at 18:30, five days following the second shot, the patient experienced a sudden outbreak of hives on his torso, armpits and groin. The hives settled but returned suddenly the following day, but less severe. A small outbreak occurred late in the third day. None had occurred since. Therapeutic measures were taken as a result of a sudden outbreak of hives on his torso, armpits and groin and included treatment with Bendryl pills. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event five days following the second shot experienced a sudden outbreak of hives on torso, armpits and groin; the hives settled but returned suddenly the following day, but less severe; a small outbreak occurred late in the third day was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness
Clinical narrative: Flu like symptoms; This is a spontaneous report from a contactable consumer. An adult female patient of an unknown age received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Apr2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown if the patient received any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On an unknown date in Apr2021, the patient experienced flu like symptoms. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. It was unknown whether any therapeutic measures were taken as a result of the event. The clinical outcome of the event flu like symptoms was unknown at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Hot flush, Pain, Pyrexia
Clinical narrative: Fever; Body pain; Vomiting; Chills; Headache; Hot flashes; Injection site pain; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 21Apr2021 at 12:45 (at the age of 25-years-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, hypermobility, major depression and latex allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included armodafinil (NUVIGIL), vortioxetine hydrobromide (TRINTELLIX), estradiol (MANUFACTURER UNKNOWN), bupropion hydrochloride (WELLBUTRIN) and midodrine (MANUFACTURER UNKNOWN); all for an unknown indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 31Mar2021 at 12:45 (at the age of 25-years-old), as a single dose for COVID-19 immunisation and previously received gabapentin (NEURONTIN) and dimenhydrinate (DRAMAMINE); both for an unknown indication from unknown date and experienced drug allergy. On 22Apr2021 at 04:30, the patient experienced fever, body pain, vomiting, chills, headache, hot flashes and injection site pain. The adverse events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event fever, body pain, vomiting, chills, headache, hot flashes and injection site pain was recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vomiting
Clinical narrative: Fever; Body pain; Vomiting; Chills; Headache; Hot flashes; Injection site pain; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 21Apr2021 at 12:45 (at the age of 25-years-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, hypermobility, major depression and latex allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included armodafinil (NUVIGIL), vortioxetine hydrobromide (TRINTELLIX), estradiol (MANUFACTURER UNKNOWN), bupropion hydrochloride (WELLBUTRIN) and midodrine (MANUFACTURER UNKNOWN); all for an unknown indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 31Mar2021 at 12:45 (at the age of 25-years-old), as a single dose for COVID-19 immunisation and previously received gabapentin (NEURONTIN) and dimenhydrinate (DRAMAMINE); both for an unknown indication from unknown date and experienced drug allergy. On 22Apr2021 at 04:30, the patient experienced fever, body pain, vomiting, chills, headache, hot flashes and injection site pain. The adverse events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event fever, body pain, vomiting, chills, headache, hot flashes and injection site pain was recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Pruritus, Rash
Clinical narrative: Rash on face; Rash on both arms; itchiness; lightheadedness; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 22Apr2021 at 09:30 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, seasonal allergy and allergic to sulfa and penicillin vk. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any other medication within two weeks of vaccination. On 22Apr2021 at 09:30, the patient experienced rash on both arms and face, accompanied by itchiness that lasted roughly 30 minutes and slight lightheadedness too. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash on both arms and face, itchiness and lightheadedness were recovered on an unknown date in Apr2021 at the time of this report.   No follow-up attempts are needed. No further information is expected.